Gemcitabine, oxaliplatin and dexamethasone as salvage treatment for elderly patients with refractory and relapsed peripheral T-cell lymphoma

Leukemia and Lymphoma

Volumn 54, Issue 6, 2013, Pages 1194-1200

  Yao, Yi Yun ^a   Tang, Yong ^a   Zhu, Qi ^a   Zhuang, Yan ^a   Cheng, Yi Min ^a   Wang, Lei ^a   Zou, Li Fang ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

Dexamethasone; Elderly patients; Gemcitabine; Oxaliplatin; Peripheral T cell lymphoma

Indexed keywords

DEXAMETHASONE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; OXALIPLATIN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CARDIOTOXICITY; CLINICAL ARTICLE; DRUG DOSE REDUCTION; ERYTHROCYTE TRANSFUSION; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GERIATRIC PATIENT; HEART PALPITATION; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; SALVAGE THERAPY; SIDE EFFECT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DEXAMETHASONE; FEMALE; HUMANS; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PILOT PROJECTS; RECURRENCE; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 84877767976     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.739286     Document Type: Article

References (25)

1. Anderson JR, Armitage JO, Weisenburger DD . Epidemiology of the non-Hodgkin ' s lymphomas: Distributions of the major subtypes diff er by geographic locations . Non-Hodgkin ' s Lymphoma Classification Project. Ann Oncol 1998; 9 : 717 - 720.
2. Nakamura S, Koshikawa T, Koike K, et al . Phenotypic analysis of peripheral T cell lymphoma among the Japanese . Acta Pathol Jpn 1993; 43 : 396 - 412.
3. V ose J, A rmitage J, W eisenburger D. I nternational peripheral T-cell and natural killer/T-cell lymphoma study: Pathology fi ndings and clinical outcomes . J Clin Oncol 2008; 26: 4124- 4130.
4. Kim K, Kim WS, Jung CW, et al . Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification . Eur J Cancer 2002; 38 : 75 - 81.
5. ArrowsmiTher, Macon WR, Kinney MC, et al . Peripheral T-cell lymphomas: Clinical features and prognostic factors of 92 cases defi ned by the revised European American lymphoma classifi cation. Leuk Lymphoma 2003; 44: 241- 249.
6. Rudiger T, Weisenburger DD, Anderson JR, et al . Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma):results from the Non-Hodgkin ' s Lymphoma Classification Project . Ann Oncol 2002; 13 : 140 - 149.
7. Escalon MP, Liu NS, Yang Y, et al . Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma:the M. D. Anderson Cancer Center experience. Cancer 2005; 103 : 2091 - 2098.
8. Philip T, Guglielmi C, Hagenbeek A, et al . Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin ' s lymphoma . N Engl J Med 1995; 333 : 1540 - 1545.
9. Dumontet C, Th ieblemont C, Espinouse D, Bouafi a F, Hequet O, Salles G, Coiffi er B. A prospective study of intensive induction therapy with high-dose consolidation in patients with aggressive non- Hodgkin ' s lymphoma and two or three adverse prognostic factors. Leukemia 2000; 14: 2159- 2165.
10. Rodriguez-Monge EJ, Cabanillas F . Long-term follow-up of platinum-based lymphoma salvages regimens . The M.D. Anderson Cancer Center experience. Hematol Oncol Clin North Am 1997; 11 : 937 - 947.
11. Zinzani PL, Baliva G, Magagnoli M, et al . Gemcitabine treatment in pretreated cutaneous T-cell lymphoma:experience in 44 patients. J Clin Oncol 2000; 18 : 2603 - 2606.
12. Sallah S, Wehbie R, Lepera P, Sallah W, Bobzien W . The role of 2-chlorodeoxyadenosine in the treatment of patients with refractory angioimmunoblastic lymphadenopathy with dysproteinemia . Br J Haematol 1999; 104 : 163 - 165.
13. Duvic M, Talpur R, Wen S, et al . Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma . Clin Lymphoma Myeloma 2006; 7 : 51 - 58.
14. Crump M, Baetz T, Couban S, et al . Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma:a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer 2004; 101 : 1835 - 1842.
15. C hau I, W ebb A, C unningham D, et a l. A n oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin' s lymphoma . Br J Haematol 2001; 115: 786 - 792.
16. Rigacci L, Fabbri A, Puccini B, et al . Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin) - /- rituximab is an eff ective salvage regimen in patients with relapsed or refractory lymphoma . Cancer 2010; 116: 4573- 4579.
17. F aivre S, R aymond E, W oynarowski J M, et a l. S upraadditive effect of 2 ', 2 ' -difl uorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines . Cancer Chemother Pharmacol 1999; 44 : 117 - 123.
18. E l G T, D upuis J, B elhadj K, et a l. R ituximab, gemcitabine and oxaliplatin: An eff ective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy . Ann Oncol 2007; 18 : 1363 - 1368.
19. C orazzelli G, R usso F, C apobianco G, et a l. G emcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new eff ective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin ' s lymphoma: Results of a pilot study . Ann Oncol 2006; 17(Suppl. 4): 18- 24.
20. Jaffe ES, Harris NL, Stein H, et al., editors. Pathology & genetics: Tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2001.
21. Cheson BD, Horning SJ, Coiffi er B, et al . Report of an international workshop to standardize response criteria for non- Hodgkin ' s lymphomas . NCI Sponsored International Working Group. J Clin Oncol 1999; 17 : 1244.
22. Evens AM, Gartenhaus RB . Treatment of T-cell non-Hodgkin ' s lymphoma . Curr Treat Options Oncol 2004; 5: 289- 303.
23. Z ain J M, O ' C onnor O. T argeted treatment and new agents in peripheral T-cell lymphoma . Int J Hematol 2010; 92: 33- 44.
24. O ' C onnor O A. N ovel agents in development for peripheral T-cell lymphoma . Semin Hematol 2010; 47(Suppl. 1): S11- S14.
25. Ng M, Waters J, Cunningham D, et al . Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an eff ective salvage regimen in patients with relapsed and refractory lymphoma . Br J Cancer 2005; 92 : 1352 - 1357.